CytoMed Therapeutics (GDTC) Current Assets (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Current Assets for 5 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 37.35% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 37.35% year-over-year, with the annual reading at $2.8 million for FY2025, 35.15% down from the prior year.
  • Current Assets hit $2.8 million in Q4 2025 for CytoMed Therapeutics, down from $4.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $7.5 million in Q4 2023 to a low of $1.8 million in Q4 2022.
  • Historically, Current Assets has averaged $3.8 million across 5 years, with a median of $2.8 million in 2025.
  • Biggest five-year swings in Current Assets: soared 316.17% in 2023 and later plummeted 39.68% in 2024.
  • Year by year, Current Assets stood at $2.4 million in 2021, then fell by 25.69% to $1.8 million in 2022, then skyrocketed by 316.17% to $7.5 million in 2023, then tumbled by 39.68% to $4.5 million in 2024, then crashed by 37.35% to $2.8 million in 2025.
  • Business Quant data shows Current Assets for GDTC at $2.8 million in Q4 2025, $4.5 million in Q4 2024, and $7.5 million in Q4 2023.